Implications of gliotransmission for the pharmacotherapy of CNS disorders

Daniela Rossi, Francesca Martorana, Liliana Brambilla

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The seminal discovery that glial cells, particularly astrocytes, can release a number of gliotransmitters that serve as signalling molecules for the cross-talk with neighbouring cellular populations has recently changed our perception of brain functioning, as well as our view of the pathogenesis of several disorders of the CNS. Since glutamate was one of the first gliotransmitters to be identified and characterized, we tackle the mechanisms that underlie its release from astrocytes, including the Ca2 signals underlying its efflux from astroglia, and we discuss the involvement of these events in a number of relevant physiological processes, from the modulatory control of neighbouring synapses to the regulation of blood supply to cerebral tissues. The relevance of these mechanisms strongly indicates that the contribution of glial cells and gliotransmission to the activities of the brain cannot be overlooked, and any study of CNS physiopathology needs to consider glial biology to have a comprehensive overview of brain function and dysfunction. Abnormalites in the signalling that controls the astrocytic release of glutamate are described in several experimental models of neurological disorders, for example, AIDS dementia complex, Alzheimers disease and cerebral ischaemia. While the modalities of glutamate release from astrocytes remain poorly understood, and this represents a major impediment to the definition of novel therapeutic strategies targeting this process at the molecular level, some key mediators deputed to the control of the glial release of this excitatory amino acid have been identified. Among these, we can mention, for instance, proinflammatory cytokines, such as tumour necrosis factor-α, and prostaglandins. Agents that are able to block the major steps of tumour necrosis factor-α and prostaglandin production andor signalling can be proposed as novel therapeutic targets for the treatment of these disorders.

Original languageEnglish
Pages (from-to)641-658
Number of pages18
JournalCNS Drugs
Volume25
Issue number8
DOIs
Publication statusPublished - 2011

Fingerprint

Neuroglia
Astrocytes
Drug Therapy
Glutamic Acid
Prostaglandins
Brain
Tumor Necrosis Factor-alpha
AIDS Dementia Complex
Physiological Phenomena
Excitatory Amino Acids
Nervous System Diseases
Brain Ischemia
Synapses
Alzheimer Disease
Theoretical Models
Cytokines
Therapeutics
Population

Keywords

  • Acquired-immunodeficiency-syndrome
  • Alzheimers-disease
  • Cerebral-ischaemia
  • CNS-disorders
  • Cyclo-oxygenase-2-inhibitors
  • Dementia
  • Etanercept
  • Memantine
  • NMDA-receptor-antagonists
  • Tumour-necrosis-factor-inhibitors.

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Clinical Neurology

Cite this

Implications of gliotransmission for the pharmacotherapy of CNS disorders. / Rossi, Daniela; Martorana, Francesca; Brambilla, Liliana.

In: CNS Drugs, Vol. 25, No. 8, 2011, p. 641-658.

Research output: Contribution to journalArticle

@article{35c315dae65743db9fccee183f57bc9f,
title = "Implications of gliotransmission for the pharmacotherapy of CNS disorders",
abstract = "The seminal discovery that glial cells, particularly astrocytes, can release a number of gliotransmitters that serve as signalling molecules for the cross-talk with neighbouring cellular populations has recently changed our perception of brain functioning, as well as our view of the pathogenesis of several disorders of the CNS. Since glutamate was one of the first gliotransmitters to be identified and characterized, we tackle the mechanisms that underlie its release from astrocytes, including the Ca2 signals underlying its efflux from astroglia, and we discuss the involvement of these events in a number of relevant physiological processes, from the modulatory control of neighbouring synapses to the regulation of blood supply to cerebral tissues. The relevance of these mechanisms strongly indicates that the contribution of glial cells and gliotransmission to the activities of the brain cannot be overlooked, and any study of CNS physiopathology needs to consider glial biology to have a comprehensive overview of brain function and dysfunction. Abnormalites in the signalling that controls the astrocytic release of glutamate are described in several experimental models of neurological disorders, for example, AIDS dementia complex, Alzheimers disease and cerebral ischaemia. While the modalities of glutamate release from astrocytes remain poorly understood, and this represents a major impediment to the definition of novel therapeutic strategies targeting this process at the molecular level, some key mediators deputed to the control of the glial release of this excitatory amino acid have been identified. Among these, we can mention, for instance, proinflammatory cytokines, such as tumour necrosis factor-α, and prostaglandins. Agents that are able to block the major steps of tumour necrosis factor-α and prostaglandin production andor signalling can be proposed as novel therapeutic targets for the treatment of these disorders.",
keywords = "Acquired-immunodeficiency-syndrome, Alzheimers-disease, Cerebral-ischaemia, CNS-disorders, Cyclo-oxygenase-2-inhibitors, Dementia, Etanercept, Memantine, NMDA-receptor-antagonists, Tumour-necrosis-factor-inhibitors.",
author = "Daniela Rossi and Francesca Martorana and Liliana Brambilla",
year = "2011",
doi = "10.2165/11593090-000000000-00000",
language = "English",
volume = "25",
pages = "641--658",
journal = "CNS Drugs",
issn = "1172-7047",
publisher = "Adis International Ltd",
number = "8",

}

TY - JOUR

T1 - Implications of gliotransmission for the pharmacotherapy of CNS disorders

AU - Rossi, Daniela

AU - Martorana, Francesca

AU - Brambilla, Liliana

PY - 2011

Y1 - 2011

N2 - The seminal discovery that glial cells, particularly astrocytes, can release a number of gliotransmitters that serve as signalling molecules for the cross-talk with neighbouring cellular populations has recently changed our perception of brain functioning, as well as our view of the pathogenesis of several disorders of the CNS. Since glutamate was one of the first gliotransmitters to be identified and characterized, we tackle the mechanisms that underlie its release from astrocytes, including the Ca2 signals underlying its efflux from astroglia, and we discuss the involvement of these events in a number of relevant physiological processes, from the modulatory control of neighbouring synapses to the regulation of blood supply to cerebral tissues. The relevance of these mechanisms strongly indicates that the contribution of glial cells and gliotransmission to the activities of the brain cannot be overlooked, and any study of CNS physiopathology needs to consider glial biology to have a comprehensive overview of brain function and dysfunction. Abnormalites in the signalling that controls the astrocytic release of glutamate are described in several experimental models of neurological disorders, for example, AIDS dementia complex, Alzheimers disease and cerebral ischaemia. While the modalities of glutamate release from astrocytes remain poorly understood, and this represents a major impediment to the definition of novel therapeutic strategies targeting this process at the molecular level, some key mediators deputed to the control of the glial release of this excitatory amino acid have been identified. Among these, we can mention, for instance, proinflammatory cytokines, such as tumour necrosis factor-α, and prostaglandins. Agents that are able to block the major steps of tumour necrosis factor-α and prostaglandin production andor signalling can be proposed as novel therapeutic targets for the treatment of these disorders.

AB - The seminal discovery that glial cells, particularly astrocytes, can release a number of gliotransmitters that serve as signalling molecules for the cross-talk with neighbouring cellular populations has recently changed our perception of brain functioning, as well as our view of the pathogenesis of several disorders of the CNS. Since glutamate was one of the first gliotransmitters to be identified and characterized, we tackle the mechanisms that underlie its release from astrocytes, including the Ca2 signals underlying its efflux from astroglia, and we discuss the involvement of these events in a number of relevant physiological processes, from the modulatory control of neighbouring synapses to the regulation of blood supply to cerebral tissues. The relevance of these mechanisms strongly indicates that the contribution of glial cells and gliotransmission to the activities of the brain cannot be overlooked, and any study of CNS physiopathology needs to consider glial biology to have a comprehensive overview of brain function and dysfunction. Abnormalites in the signalling that controls the astrocytic release of glutamate are described in several experimental models of neurological disorders, for example, AIDS dementia complex, Alzheimers disease and cerebral ischaemia. While the modalities of glutamate release from astrocytes remain poorly understood, and this represents a major impediment to the definition of novel therapeutic strategies targeting this process at the molecular level, some key mediators deputed to the control of the glial release of this excitatory amino acid have been identified. Among these, we can mention, for instance, proinflammatory cytokines, such as tumour necrosis factor-α, and prostaglandins. Agents that are able to block the major steps of tumour necrosis factor-α and prostaglandin production andor signalling can be proposed as novel therapeutic targets for the treatment of these disorders.

KW - Acquired-immunodeficiency-syndrome

KW - Alzheimers-disease

KW - Cerebral-ischaemia

KW - CNS-disorders

KW - Cyclo-oxygenase-2-inhibitors

KW - Dementia

KW - Etanercept

KW - Memantine

KW - NMDA-receptor-antagonists

KW - Tumour-necrosis-factor-inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=79960784675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960784675&partnerID=8YFLogxK

U2 - 10.2165/11593090-000000000-00000

DO - 10.2165/11593090-000000000-00000

M3 - Article

C2 - 21790208

AN - SCOPUS:79960784675

VL - 25

SP - 641

EP - 658

JO - CNS Drugs

JF - CNS Drugs

SN - 1172-7047

IS - 8

ER -